Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: biomarker returned 30 record(s)
|
|
Sunday, 07/29/2018
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
|
Strategies for Validating Biomarkers Using Data from a Reference Set
Lu Wang, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center
2:20 PM
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
2:50 PM
|
Estimating Heterogeneous Biomarker Networks and Their Effects on Disease Outcome
Shanghong Xie, Columbia University; Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Donglin Zeng, UNC Chapel Hill; Yuanjia Wang, Columbia University
4:05 PM
|
|
Monday, 07/30/2018
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
|
Missing Data Framework for Estimating Biomarker Clinical Utility Under Incomplete Follow-Up
Julie Kobie, Merck Research Laboratories; Lingkang Huang, Merck Research Laboratories; Robin Mogg, Merck Research Laboratories; Jared Lunceford, Merck Research Laboratories
8:50 AM
|
Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making
Weidong Zhang, Pfizer Inc.
10:35 AM
|
Design and Analysis Considerations for Studies Involving Pooled Biomarker Data
Abigail Sloan, Harvard T.H. Chan School of Public Health; Molin Wang, Harvard T.H. Chan School of Public Health; Mitchell H. Gail, Division of Cancer Epidemiology and Genetics, NCI, NIH
10:50 AM
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
11:15 AM
|
Developing Biomarker Combinations in Multicenter Studies via Direct Maximization and Penalization
Allison Meisner, Johns Hopkins University; Kathleen F. Kerr, University of Washington; Chirag Parikh, Yale University
11:35 AM
|
Identifying Biomarkers in Heterogeneous Samples Without Known Reference Cell Type Profiles
Kelly Mosesso, Harvard University ; Martin Aryee, Harvard University
11:35 AM
|
Bessel Functions and the Ordering of Changes in Biomarkers, with Application to the Hypothesized Biomarker Model in Preclinical Alzheimer Disease
Chengjie Xiong, Washington University in St Louis; Jingqin Luo, Washington University; John Morris, Washington University
12:05 PM
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
2:20 PM
|
Statistical Considerations for Using Multiple Databases to Build a Biomarker Probability Tool
Feng Gao; Shijia Bian, Biogen; Wenting Wang, Biogen; Nancy Maserejian, Biogen; Judith Jaeger, Albert Einstein College of Medicine; Robert Robert Engle , Biogen; Timothy Swan, Biogen; James McIninch, Alnylam Pharmaceuticals; Feng Gao, Biogen
2:25 PM
|
Powering Biomarker Discovery Studies for Training and Validation
Olga Demler, Harvard Medical School; Nancy R Cook, Harvard Medical School
3:35 PM
|
|
Tuesday, 07/31/2018
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
|
Statistical Considerations for Using Multiple Databases to Build a Biomarker Probability Tool
Feng Gao; Shijia Bian, Biogen; Wenting Wang, Biogen; Nancy Maserejian, Biogen; Judith Jaeger, Albert Einstein College of Medicine; Robert Robert Engle , Biogen; Timothy Swan, Biogen; James McIninch, Alnylam Pharmaceuticals; Feng Gao, Biogen
|
Issues Regarding Biomarker Combination Within ROC Framework: Strategies, Target Functions, and Large Number of Weak Markers
Lili Tian, SUNY at Buffalo; Li Yan, Roswell Park Cancer Institute; Jingjing Yin, Georgia Southern University; Le Kang, Virginia Commonwealth University
8:35 AM
|
Data-Driven Biomarker Evaluation in Adaptive Designs Using SIDES
Ilya Lipkovich, IQVIA; Alex Dmitrienko, Mediana Inc
8:35 AM
|
Robust Combination of Biomarkers for Classification with Covariate Adjustment
Ying Huang, Fred Hutchinson Cancer Research Center; Soyoung Kim, Medical College of Wisconsin
8:55 AM
|
Developing Genomic Biomarker to Guide Personalized Patient Management in Oncology: Validity and Utility of Clinical Diagnostic Applications
Michael Crager, Genomic Health; Ruixiao Lu, Genomic Health, Inc.
11:25 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
Estimating Directed Acyclic Graphs from High-Dimensional Data and Its Application in Biomarker Discoveries in Early Clinical Trials
Hua Zhong, New York University; Jaehong Yu, NYU School of Medicine
11:55 AM
|
A Bayesian Framework for Calculating Predictive Probability of Success in Biomarker Development
Cong Li; Ling Wang, Takeda; Ray Liu, Takeda Pharmaceuticals Inc
2:05 PM
|
Reproducibility of FDG-PET Standardized Uptake Value (SUV) for Use as an Integral Biomarker in Clinical Trials
Brenda Kurland, University of Pittsburgh
3:05 PM
|
|
Thursday, 08/02/2018
|
Adjusting for Handling Effects in Microarray Data for Prognostic Biomarker Discovery and Survival Risk Prediction
Ai Ni, Memorial Sloan Kettering Cancer Center; Mengling Liu, New York University; Li-Xuan Qin, Memorial Sloan Kettering Cancer Center
9:05 AM
|
Using Surrogate Biomarker Information to Plan a Future Clinical Trial
Layla Parast, RAND; Tianxi Cai, Harvard T.H. Chan School of Public Health; Lu Tian, Stanford University School of Medicine
11:00 AM
|
Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM
|
Evaluating the Ability of a Biomarker to Improve the Diagnosis of Malaria Infection in Malaria 'Challenge' Trials
Holly Janes, Fred Hutchinson Cancer Research Center
11:50 AM
|
|
|
